论文部分内容阅读
目的评价吡柔比星+泰素帝联合奇宁注射液治疗晚期乳腺癌临床疗效及不良反应。方法42例患者均有病理学诊断及可评价的客观指标,且全部为复治的Ⅳ期患者,随机分为两组,A组:吡柔比星+泰素帝联合奇宁注射液;B组:吡柔比星+泰素帝。结果A组有效率为67%,B组有效率为62%。不良反应主要为白细胞减少,但A组较B组明显减轻。结论吡柔比星+泰素帝是治疗晚期乳腺癌的有效方案,加用奇宁注射液可降低骨髓抑制作用。
Objective To evaluate the clinical efficacy and side effects of pirarubicin + taxol combined with Cynanchum injection in the treatment of advanced breast cancer. Methods Forty-two patients were pathologically diagnosed and evaluated as objective indicators. All of them were stage Ⅳ patients of retreatment. Patients in group Ⅳ were randomly divided into two groups. Group A: pirarubicin + taxol combined with Qining Injection; B Group: Pirarubicin + Taxotere. Results The effective rate of group A was 67% and that of group B was 62%. Adverse reactions mainly leukopenia, but A group was significantly reduced compared with the B group. Conclusion Pirarubicin + Taxotere is an effective treatment for advanced breast cancer. Adding Cynanchum injection can reduce bone marrow suppression.